Supernus Pharma’s ADHD treatment meets main goal in two studies

Share this post

Supernus Pharmaceuticals Inc on Thursday said its experimental treatment for attention deficit hyperactivity disorder met the main goal of reducing symptoms in affected children from six to 11 years of age in two late-stage studies.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply